India's Glenmark Gets Arbitrator Nod to Sell Crofelemer Drug

The International Center for Dispute Resolution has ruled that India’s Glenmark Pharmaceuticals has the right to sell Crofelemer, its drug for HIV-associated diarrhea, in 140 countries. The medication was developed by Glenmark with US-based partners Napo Pharmaceuticals and Salix Pharmaceuticals Ltd.

Glenmark sought arbitration in the United States in December, after Napo terminated a three-party agreement that gave Glenmark exclusive distribution rights for Crofelemer in India and 139 other nations. In a statement, Glenmark said the ICDR found that Napo breached the agreement by revealing confidential information about manufacturing Crofelemer to Aptuit Laurus, another drugmaker.

Glenn Saldanha, Glenmark’s chair, said the ruling will permit the company “to further its commitment to working with relief agencies to distribute Crofelemer to affected populations.”

The Friends of AIDS Foundation is dedicated to enhancing the quality of life for HIV positive individuals and empowering people to make healthy choices to prevent the spread of the HIV virus. To learn more about The Friends of AIDS Foundation, please visit: http://www.friendsofaids.org.

TOGETHER WE REMAIN STRONG!